Anti-Human CD45/PTPRC Antibody (BC8), FITC

Anti-Human CD45/PTPRC Antibody (BC8), FITC: A Potent Therapeutic Target for Immunotherapy

Introduction

The human CD45/PTPRC protein is a transmembrane tyrosine phosphatase that is expressed on all nucleated hematopoietic cells. It plays a critical role in regulating immune cell signaling and activation. Dysregulation of CD45/PTPRC has been linked to various immune disorders, making it a promising therapeutic target for immunotherapy. One such tool for targeting CD45/PTPRC is the Anti-Human CD45/PTPRC Antibody (BC8), FITC.

Structure of Anti-Human CD45/PTPRC Antibody (BC8), FITC

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is a monoclonal antibody that specifically binds to the extracellular domain of CD45/PTPRC. It is conjugated with fluorescein isothiocyanate (FITC), a green fluorescent dye, for visualization and detection purposes. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of constant and variable regions, while the light chains only have variable regions.

Activity of Anti-Human CD45/PTPRC Antibody (BC8), FITC

The Anti-Human CD45/PTPRC Antibody (BC8), FITC binds to CD45/PTPRC with high specificity and affinity, inhibiting its activity as a phosphatase. This leads to downstream effects on immune cell signaling and activation. The FITC conjugate allows for easy visualization and tracking of CD45/PTPRC expression and localization in cells and tissues. This antibody has been shown to effectively target CD45/PTPRC on various immune cells, including T cells, B cells, and natural killer cells.

Application of Anti-Human CD45/PTPRC Antibody (BC8), FITC

The Anti-Human CD45/PTPRC Antibody (BC8), FITC has several applications in both research and therapeutic settings. In research, it is commonly used to study the expression and function of CD45/PTPRC in different immune cell types and diseases. The FITC conjugate allows for flow cytometric analysis and immunofluorescence imaging, providing valuable insights into the role of CD45/PTPRC in immune cell biology.
In therapeutic settings, the Anti-Human CD45/PTPRC Antibody (BC8), FITC has shown potential for use in immunotherapy. By targeting CD45/PTPRC, it can modulate immune cell signaling and activation, making it a promising tool for treating immune disorders such as autoimmune diseases and cancer. Additionally, the FITC conjugate can be used for targeted delivery of therapeutics to CD45/PTPRC-expressing cells, enhancing their efficacy and reducing off-target effects.

Conclusion

The Anti-Human CD45/PTPRC Antibody (BC8), FITC is a highly specific and potent tool for targeting CD45/PTPRC, a critical regulator of immune cell signaling and activation. Its structure, activity, and applications make it a valuable resource for both research and therapeutic purposes. Further studies on this antibody and its potential as a therapeutic target are warranted to fully harness its benefits in immunotherapy.